Skip to main content
Vivos Therapeutics, Inc. logo

Vivos Therapeutics, Inc. — Investor Relations & Filings

Ticker · VVOS ISIN · US92859E1082 US Manufacturing
Open in API
Filings indexed 259 across all filing types
Latest filing 2024-02-14 Major Shareholding Noti…
Country US United States of America
Listing US VVOS

About Vivos Therapeutics, Inc.

https://vivos.com/

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for sleep-disordered breathing, including obstructive sleep apnea (OSA). The company's core offering is The Vivos System, a non-surgical treatment that uses proprietary oral appliances. These devices are designed to address underlying dentofacial abnormalities that can restrict the airway. The treatment protocol aims to promote the natural growth and development of the jaw and airway in both adult and pediatric patients. Vivos provides its technology and training to a network of licensed dentists and medical professionals who deliver the therapy.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2024
Major Shareholding Notification
2024-02-14 English
Regulatory Filings 2023
Regulatory Filings
2023-12-04 English
Capital/Financing Update 2023
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(1) related to the offer for sale of common stock and warrants by a selling stockholder. It includes extensive information about the company, its products, risk factors, use of proceeds, management discussion and analysis, executive compensation, principal stockholders, and legal matters. The document is clearly a registration and offering prospectus for securities, not a financial report, earnings release, or management discussion report. It is not an announcement or brief summary but a full prospectus document intended for investors. This type of filing corresponds to a Capital/Financing Update category, as it relates to fundraising and securities offering activities.
2023-12-01 English
Capital/Financing Update 2023
Capital/Financing Update Classification · 95% confidence The document is a letter from Vivos Therapeutics, Inc. to the SEC requesting acceleration of effectiveness of a Registration Statement on Form S-1. It references the Securities Act of 1933 and the filing number for the registration statement. The content is a formal communication related to a securities registration process, specifically about the timing of the effectiveness of the registration statement. It does not contain financial data, earnings, management discussion, or any report content. It is not a report itself but a regulatory communication related to capital raising. Therefore, it fits best under Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2023-12-01 English
Delisting Announcement 2023
Delisting Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. The content focuses on the company's receipt of notices from Nasdaq regarding non-compliance with listing requirements, details about a reverse stock split, a hearing with the Nasdaq panel, and an extension granted to regain compliance. It discusses delisting proceedings and capital raising efforts but does not contain financial statements or detailed financial analysis. The document is an announcement of events related to delisting and compliance status rather than a full financial report or earnings release. Therefore, it fits the category of a Delisting Announcement (DLST). The document length is 6822 characters, which is sufficient to contain substantive information, not just a brief notice. Hence, the classification is DLST with high confidence.
2023-11-30 English
Capital/Financing Update 2023
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A Registration Statement filed with the U.S. Securities and Exchange Commission. It is an amendment to a registration statement under the Securities Act of 1933, related to the registration of shares for sale by a selling stockholder. The document includes a preliminary prospectus with detailed information about the company, the offering, risk factors, use of proceeds, management discussion, and other disclosures typical of a registration statement for an initial or secondary public offering. This type of filing is related to capital raising activities and securities registration, not an annual report, earnings release, or other financial report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a report publication announcement but a substantive filing related to capital raising.
2023-11-30 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.